Please use this identifier to cite or link to this item:
Title: Diabetic Retinopathy and Ocular Melanoma: How far we are?
Author: Souto, Eliana B.
Campos, Joana R.
Da Ana, Raquel
Fangueiro, Joana F.
Martins-Gomes, Carlos
Durazzo, Alessandra
Lucarini, Massimo
Sánchez-López, E. (Elena)
Espina García, Marta
García López, María Luisa
Silva, Amélia M.
Mendonça, Fernando
Santini, Antonello
Souto, Selma B.
Keywords: Angiogènesi
Factor de creixement de l'endoteli vascular
Retinopatia diabètica
Vascular endothelial growth factors
Diabetic retinopathy
Issue Date: 16-Apr-2020
Publisher: MDPI
Abstract: Diabetic retinopathy causes vascular damage to retinal neurons, presenting characteristics of chronic inflammation. The development of new therapies capable of combating vision loss involves knowledge of inflammatory retinal changes. Studies in animal models and patients with diabetes have shown a high expression of the inflammatory molecules that are involved in the progression of diabetic retinopathy. Uveal melanoma is an eye tumour that remains highly deadly, because despite the correct treatment, it still causes metastasis in about 50% of patients. This type of tumour has the ability to produce and store melanin, which may result in resistance to therapy. Over time there has been development of new therapies for this disease, such as radiotherapy and surgical resection. In this review, we discuss diabetic retinopathy and ocular melanoma, their relationship with angiogenesis and the current anti-angiogenic therapies for their treatment
Note: Reproducció del document publicat a:
It is part of: Applied Sciences, 2020, vol. 10, p. 2777-
Related resource:
ISSN: 2076-3417
Appears in Collections:Articles publicats en revistes (Institut de Nanociència i Nanotecnologia (IN2UB))
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
701339.pdf993.6 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons